The U.S. Food and Drug Administration (FDA) on Sept. 3 approved AstraZeneca’s Brilinta (ticagrelor) for long-term use in smaller, 60mg doses. The expanded approval is intended for patients with a history of heart attacks.

The results of the PEGASUS-TIMI 54 clinical trial, presented at ACC’s 64th Annual Scientific Sessions, showed that stable heart attack patients benefited from taking ticagrelor beyond the first year after a heart attack. Overall, patients receiving ticagrelor had reduced chances of cardiovascular mortality, heart attack or stroke.

Keywords: Adenosine, Drug Approval, Myocardial Infarction, Stroke, United States Food and Drug Administration, Purinergic P2Y Receptor Antagonists

< Back to Listings